BAY-6096 |
BAY-6096 : Antagonist of ADRA2B
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download
Probe Summary
| Targets | Biochemical/Biophysical Potency | Cellular Potency |
|---|---|---|
| ADRA2B |
|
|
Antagonist
100 nM
Selectivity
In Vitro Selectivity Assessment
Potency Assay Off-Target:
Selectivity within target family: Adrenergic receptor panel (IC50): ADRA1A (5.516 µM; 394- fold), AD ...
Potency Cellular
In Vitro
ADRA2B
Mode of Action: Antagonist
Structure-Activity-Relationship data available? No
DOI Reference: 10.1021/acs.jmedchem.2c01690
In Vivo Validations
Rat
Dose: 0.3 mg/Kg
Route of delivery:
Intravenous
Plasma half life:
0.1 h MRT
Systemic clearance:
4.3 L/h/Kg
Fb :
21%
Volume of Distribution at Steady-State:
0.5 L/Kg
DOI Reference: 10.1021/acs.jmedchem.2c01690
Dog
Dose: 0.3 mg/Kg
Route of delivery:
Intravenous
Plasma half life:
0.4 h MRT
Systemic clearance:
1.6 L/h/Kg
Fb :
18%
Volume of Distribution at Steady-State:
0.6 L/Kg
DOI Reference: 10.1021/acs.jmedchem.2c01690
Negative Control Compounds
BAY-726
Notes: BAY-726: human ADRA2B: IC50 = 7.1 µM (Cell-based assay); Clean adrenergic receptor panel
SMILES:
Cc1c(c2cnc3cc(ccn23)C(NCCC[n+]2ccc(cc2)N(C)C)=O)c(C)on1.C([O-])=O
Chemical Information
| Molecular Formula | C21H23ClN6O2 |
| SMILEs | CNc1cc[n+](CCNC(=O)c2ccn3c(-c4c(C)noc4C)cnc3c2)cc1.[Cl-] |
| InChI | InChI=1S/C21H22N6O2.ClH/c1-14-20(15(2)29-25-14)18-13-24-19-12-16(4-10-27(18)19)21(28)23-7-11-26-8-5-17(22-3)6-9-26;/h4-6,8-10,12-13H,7,11H2,1-3H3,(H,23,28);1H |
| Molecular weight | 426.16 Da |
| AlogP | 0.0 |
| HBond acceptors | 8 |
| HBond donors | 2 |
| Atoms | 53 |